The global cartilage regeneration market accounted for USD 1.16 billion in 2023 and is expected to reach USD 5.62 billion by 2034 with a CAGR of 15.43% during the forecast period 2024-2034. The market will grow due to rising rates of joint disorders, rising demand for minimally invasive procedures, technological advancements in scaffolds and biomaterials, increased sports injuries, and expanding uses in orthopedic and sports medicine.
The orthopedics and sports medicine fields are exploring new uses for cartilage regeneration technology outside of the more conventional ones, such as osteoarthritis. The market is expanding as a result of these therapies' increased use in treating a wider variety of cartilage lesions, such as those caused by degenerative disorders, trauma, and sports injuries. For instance, Smith & Nephew's ReGen Advantage meniscal repair system received FDA 510(k) certification in the United States in February 2024. This minimally invasive technique treats a different kind of knee cartilage injury.
By type, the hyaline cartilage segment accounted for the highest revenue-grossing segment in the global cartilage regeneration market in 2023 owing to the high demand for hyaline cartilage regeneration therapies to treat osteoarthritis and sports injuries, coupled with advancements in tissue engineering techniques tailored for hyaline cartilage repair. For instance, Zimmer Biomet and Arthrogenics announced a partnership in April 2024 to develop next-generation cartilage repair solutions using biologic medicines. Additionally, the fibrocartilage segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of fibrocartilage injuries in athletes and active individuals, coupled with ongoing research and development efforts to enhance regenerative therapies specifically targeted towards fibrocartilage repair.
By treatment modality, the cell-based segment accounted for the highest revenue-grossing segment in the global cartilage regeneration market in 2023 owing to the efficacy of cell-based therapies in promoting cartilage regeneration and repairing tissue defects, supported by advancements in stem cell research, tissue engineering, and biotechnology. For instance, in March 2024, Anika reports favorable long-term outcomes from a clinical trial including its Hyaluronate Arthroscopy (HA) treatment for osteoarthritis in the knee, indicating promise for supporting cartilage regeneration. Additionally, the stem cell therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of stem cell-based approaches for cartilage regeneration, driven by their potential to differentiate into chondrocytes and stimulate tissue repair, alongside ongoing clinical trials and advancements in stem cell technology.
By application site, the knee segment accounted for the highest revenue-grossing segment in the global cartilage regeneration market in 2023 owing to the prevalence of knee-related cartilage injuries, including osteoarthritis and sports-related trauma, coupled with high demand for effective treatment options and advancements in knee-specific regenerative therapies. For instance, in March 2024, Histogenics announces that it has formed a strategic alliance with a prominent orthopedic company (name withheld) to advance the development of its NeoCart® cartilage healing product. Additionally, the shoulder segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of shoulder injuries, particularly in athletes and aging populations, along with advancements in shoulder-specific regenerative therapies and minimally invasive surgical techniques.
By surgical procedure, the arthroscopic chondroplasty segment accounted for the highest revenue-grossing segment in the global cartilage regeneration market in 2023 owing to the growing preference for minimally invasive procedures for cartilage repair, coupled with the widespread adoption of arthroscopic chondroplasty techniques for addressing cartilage lesions in various joints. For instance, RTI Surgical announced the full commercial introduction of Meniscal Repair System (MRS), its next-generation meniscal repair solution, in April 2024. Additionally, the autologous chondrocyte implantation segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for personalized cartilage repair solutions, advancements in tissue engineering, and the potential of autologous chondrocyte implantation to provide long-term functional outcomes with reduced risk of immune rejection.
By end-user, the hospitals and clinics segment accounted for the highest revenue-grossing segment in the global cartilage regeneration market in 2023 owing to the high patient footfall for orthopedic procedures, availability of advanced surgical facilities, and increasing adoption of cartilage regeneration therapies in hospital and clinic settings. For instance, in March 2024, CollPlant will publish encouraging preclinical data at the Orthopaedic Research Society (ORS) Annual Meeting regarding its Bio-Regen implant for cartilage healing. Additionally, the ambulatory surgical centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for outpatient procedures, advancements in minimally invasive surgical techniques, and the convenience and cost-effectiveness offered by ambulatory surgical centers for cartilage regeneration procedures.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of musculoskeletal disorders, robust healthcare infrastructure, increasing adoption of advanced medical technologies, and supportive reimbursement policies for cartilage regeneration therapies in North America. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness about cartilage regeneration therapies, increasing healthcare expenditure, expanding geriatric population, and advancements in healthcare infrastructure in the Asia Pacific region. For instance, Orthocell wins CE Mark clearance for its OrthoStrip® product in Europe in February 2024. OrthoStrip® is a collagen membrane that is utilized for a variety of purposes, including cartilage restoration.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
The orthopedics and sports medicine fields are exploring new uses for cartilage regeneration technology outside of the more conventional ones, such as osteoarthritis. The market is expanding as a result of these therapies' increased use in treating a wider variety of cartilage lesions, such as those caused by degenerative disorders, trauma, and sports injuries. For instance, Smith & Nephew's ReGen Advantage meniscal repair system received FDA 510(k) certification in the United States in February 2024. This minimally invasive technique treats a different kind of knee cartilage injury.
By type, the hyaline cartilage segment accounted for the highest revenue-grossing segment in the global cartilage regeneration market in 2023 owing to the high demand for hyaline cartilage regeneration therapies to treat osteoarthritis and sports injuries, coupled with advancements in tissue engineering techniques tailored for hyaline cartilage repair. For instance, Zimmer Biomet and Arthrogenics announced a partnership in April 2024 to develop next-generation cartilage repair solutions using biologic medicines. Additionally, the fibrocartilage segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of fibrocartilage injuries in athletes and active individuals, coupled with ongoing research and development efforts to enhance regenerative therapies specifically targeted towards fibrocartilage repair.
By treatment modality, the cell-based segment accounted for the highest revenue-grossing segment in the global cartilage regeneration market in 2023 owing to the efficacy of cell-based therapies in promoting cartilage regeneration and repairing tissue defects, supported by advancements in stem cell research, tissue engineering, and biotechnology. For instance, in March 2024, Anika reports favorable long-term outcomes from a clinical trial including its Hyaluronate Arthroscopy (HA) treatment for osteoarthritis in the knee, indicating promise for supporting cartilage regeneration. Additionally, the stem cell therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of stem cell-based approaches for cartilage regeneration, driven by their potential to differentiate into chondrocytes and stimulate tissue repair, alongside ongoing clinical trials and advancements in stem cell technology.
By application site, the knee segment accounted for the highest revenue-grossing segment in the global cartilage regeneration market in 2023 owing to the prevalence of knee-related cartilage injuries, including osteoarthritis and sports-related trauma, coupled with high demand for effective treatment options and advancements in knee-specific regenerative therapies. For instance, in March 2024, Histogenics announces that it has formed a strategic alliance with a prominent orthopedic company (name withheld) to advance the development of its NeoCart® cartilage healing product. Additionally, the shoulder segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of shoulder injuries, particularly in athletes and aging populations, along with advancements in shoulder-specific regenerative therapies and minimally invasive surgical techniques.
By surgical procedure, the arthroscopic chondroplasty segment accounted for the highest revenue-grossing segment in the global cartilage regeneration market in 2023 owing to the growing preference for minimally invasive procedures for cartilage repair, coupled with the widespread adoption of arthroscopic chondroplasty techniques for addressing cartilage lesions in various joints. For instance, RTI Surgical announced the full commercial introduction of Meniscal Repair System (MRS), its next-generation meniscal repair solution, in April 2024. Additionally, the autologous chondrocyte implantation segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for personalized cartilage repair solutions, advancements in tissue engineering, and the potential of autologous chondrocyte implantation to provide long-term functional outcomes with reduced risk of immune rejection.
By end-user, the hospitals and clinics segment accounted for the highest revenue-grossing segment in the global cartilage regeneration market in 2023 owing to the high patient footfall for orthopedic procedures, availability of advanced surgical facilities, and increasing adoption of cartilage regeneration therapies in hospital and clinic settings. For instance, in March 2024, CollPlant will publish encouraging preclinical data at the Orthopaedic Research Society (ORS) Annual Meeting regarding its Bio-Regen implant for cartilage healing. Additionally, the ambulatory surgical centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for outpatient procedures, advancements in minimally invasive surgical techniques, and the convenience and cost-effectiveness offered by ambulatory surgical centers for cartilage regeneration procedures.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of musculoskeletal disorders, robust healthcare infrastructure, increasing adoption of advanced medical technologies, and supportive reimbursement policies for cartilage regeneration therapies in North America. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness about cartilage regeneration therapies, increasing healthcare expenditure, expanding geriatric population, and advancements in healthcare infrastructure in the Asia Pacific region. For instance, Orthocell wins CE Mark clearance for its OrthoStrip® product in Europe in February 2024. OrthoStrip® is a collagen membrane that is utilized for a variety of purposes, including cartilage restoration.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Treatment Modality. Application Site, Surgical Procedures, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: Cartilage Regeneration Market Report 2023 - 2034
Cartilage Regeneration Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Fibro Cartilage
- Hyaline Cartilage
- Elastic Cartilage
- Other
Cartilage Regeneration Market Analysis & Forecast by Treatment Modality 2023 - 2034 (Revenue USD Bn)
- Cell-Based
- Chondrocyte Transplantation
- Growth Factor Technology
- Non-Cell Based
- Tissue Scaffolds
- Cell-Free Composites
Cartilage Regeneration Market Analysis & Forecast by Application Site 2023 - 2034 (Revenue USD Bn)
- Knee
- Arthroscopic Chondroplasty
- Autologous Chondrocyte
- Osteochondral Grafts Transplantation
- Cell-based Cartilage Resurfacing
- Microfracture
- Other
- Spine
- Ankle
- Hip
- Others
Cartilage Regeneration Market Analysis & Forecast by Surgical Procedures 2023 - 2034 (Revenue USD Bn)
- Chondroplasty
- Microfracture
- Autologous Chondrocyte Implantation
- Osteochondral Autograft Transplantation
- Osteochondral Allograft Transplantation
- Juvenile Allograft Fragments
- Others
Cartilage Regeneration Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Ambulatory Surgical Centers
- Hospitals and Clinics
- Surgical Centers
- Others
Cartilage Regeneration Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Cartilage Regeneration Market: Type Estimates & Trend Analysis
8. Cartilage Regeneration Market: Treatment Modality Estimates & Trend Analysis
9. Cartilage Regeneration Market: Application Site Estimates & Trend Analysis
10. Cartilage Regeneration Market: Surgical Procedure Estimates & Trend Analysis
11. Cartilage Regeneration Market: End-user Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Cartilage Regeneration Market
14. Europe Global Cartilage Regeneration Market
15. Asia Pacific Global Cartilage Regeneration Market
16. Latin America Global Cartilage Regeneration Market
17. MEA Global Cartilage Regeneration Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- Vericel Corporation
- Smith & Nephew plc
- Zimmer Biomet Holdings Inc.
- Stryker Corporation
- Anika Therapeutics Inc.
- Arthrex Inc.
- Osiris Therapeutics Inc.
- Histogenics Corporation
- B. Braun Melsungen AG
- Medtronic plc
- RTI Surgical Holdings Inc.
- CollPlant Biotechnologies Ltd.
- Orthocell Limited
- CONMED Corporation
- Bioventus LLC.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | October 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 1.16 Billion |
| Forecasted Market Value ( USD | $ 5.62 Billion |
| Compound Annual Growth Rate | 15.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
